Oasmia Pharmaceutical AB Stock NORDIC GROWTH MARKET
Equities
OASM
SE0000722365
Pharmaceuticals
Sales 2021 | 28.87M 2.67M | Sales 2022 | 3.04M 281K | Capitalization | 234M 21.6M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.3M | Net income 2022 | -357M -33.03M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 8.03M | Net cash position 2022 | 134M 12.43M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Oasmia Pharmaceutical AB
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
1st Jan change | Capi. | |
---|---|---|
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |